Back to News
Market Impact: 0.25
CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
Source: Nasdaq
Corporate EarningsCompany FundamentalsHealthcare & BiotechCorporate Guidance & Outlook
CytomX Therapeutics reported $348.0 million in cash, cash equivalents and investments at September 30, 2026, which it said is expected to fund operations into the second half of 2028. The article text cuts off after beginning to report total revenue, so no revenue figure or broader earnings details are available.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
CTMX0.25
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise